enGene (NASDAQ:ENGN) Sees Unusually-High Trading Volume – Should You Buy?

enGene Holdings Inc. (NASDAQ:ENGN) shares saw unusually-strong trading volume on Thursday . Approximately 1,441,707 shares changed hands during mid-day trading, an increase of 223% from the previous session’s volume of 446,828 shares.The stock last traded at $7.4660 and had previously closed at $6.88.

Trending Headlines about enGene

Here are the key news stories impacting enGene this week:

• Positive Sentiment: HC Wainwright raised multiple near‑ and medium‑term EPS forecasts for ENGN and reiterated a “Buy” rating with a $25 price target, trimming projected losses across FY2026–FY2029 and even forecasting positive EPS in FY2030 — the report signals improved fundamental expectations that likely prompted buying. HC Wainwright Buy Report
• Positive Sentiment: Oppenheimer maintained an “Outperform” rating while setting a $30 target (down from $33), which still implies substantial upside from current levels and may have reinforced investor conviction. Oppenheimer Coverage Note
• Positive Sentiment: Short interest has declined versus mid‑February, with the February 27 report showing ~1.24M shares short (about 2.1% of float), reducing immediate short‑covering pressure and lowering one source of near‑term downside risk. (Source: short‑interest reports)
• Neutral Sentiment: enGene presented at the Barclays 28th Annual Global Healthcare Conference — investor presentations can catalyze interest but the transcript did not contain a single headline product milestone to materially change near‑term valuation. Barclays Conference Transcript
• Neutral Sentiment: Some short‑interest reporting items in the feed are inconsistent or show zeros/NaN (likely data artifacts); these don’t provide reliable new information. (Internal short‑interest summaries)
• Neutral Sentiment: Several unrelated automotive articles appeared in the feed and are not relevant to enGene’s prospects. (No link)

Analyst Ratings Changes

Several analysts have recently commented on the company. Citizens Jmp raised their price target on enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a report on Wednesday, November 12th. Raymond James Financial restated a “strong-buy” rating and issued a $27.00 price objective on shares of enGene in a research report on Monday. UBS Group lifted their price objective on enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 12th. Guggenheim reiterated a “buy” rating on shares of enGene in a research report on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, enGene has a consensus rating of “Moderate Buy” and a consensus price target of $22.86.

enGene Trading Up 7.0%

The firm has a market cap of $493.38 million, a P/E ratio of -3.27 and a beta of -0.29. The company’s 50 day moving average is $9.46 and its two-hundred day moving average is $8.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.75 and a quick ratio of 6.30.

enGene (NASDAQ:ENGN) last released its earnings results on Monday, March 9th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.11. On average, sell-side analysts predict that enGene Holdings Inc. will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On enGene

A number of hedge funds have recently bought and sold shares of the company. XTX Topco Ltd purchased a new stake in shares of enGene in the fourth quarter valued at about $216,000. Vestal Point Capital LP increased its position in shares of enGene by 185.1% during the fourth quarter. Vestal Point Capital LP now owns 1,055,000 shares of the company’s stock valued at $9,527,000 after acquiring an additional 685,000 shares during the last quarter. Virtus Investment Advisers LLC bought a new stake in enGene during the fourth quarter worth $284,000. Quadrature Capital Ltd purchased a new position in enGene in the fourth quarter worth $439,000. Finally, Perceptive Advisors LLC increased its position in shares of enGene by 179.8% during the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock valued at $52,998,000 after purchasing an additional 3,771,840 shares during the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.